Ovarian Cancer Treatment Drugs Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Ovarian Cancer Treatment Drugs Market was valued at USD 3.5 billion in 2023 and is expected to reach USD 6.1 billion by 2032, growing at a CAGR of 6.3% over the analysis period. High incidence of ovarian cancer is a major driver for market growth. According to the World Cancer Research Fund International (WCRF), ovarian cancer ranks eighth most commonly occurring cancer in women, causing more deaths annually than any other gynecological cancer. Similarly, as per Globocan’s 2020 projections, by 2040, the number of women around the world diagnosed with ovarian cancer will rise by almost 42% to 445,721 cases. Also, the number of women dying from ovarian cancer each year is projected to increase to 313,617, an increase of over 50% from 2020. Thus, growing cases of ovarian cancer will increase the demand for treatment, thereby fostering the market growth.
Ovarian cancer treatment drugs refer to pharmaceutical agents designed to prevent and manage ovarian cancer. These drugs are developed to target and impede the growth of cancer cells, either by directly attacking them or by inhibiting specific biological processes essential for their proliferation. Ovarian cancer treatment drugs include chemotherapy agents, targeted therapies, hormone therapies, and immunotherapies, among others.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Ovarian Cancer Treatment Drugs Market size in 2023: | USD 3.5 Billion |
| Forecast Period: | 2024 to 2032 |
| Forecast Period 2023 - 2032 CAGR: | 6.3 |
| 2023 Value Projection: | USD 6.1 Billion |
| Historical Data for: | 2018 to 2023 |
| No of Pages: | 200 |
| Tables, Charts & Figures: | 317 |
| Segments Covered: | Cancer Type, Treatment Type, Route of Administration, End-user, & Region |
| Growth Drivers: |
|
| Pitfalls Challenges: |
|
The COVID-19 pandemic had a negative impact on the ovarian cancer treatment drugs market. Disruptions in healthcare services including cancer screening, delays in clinical trials, and redirected resources towards managing the pandemic impacted drug development and patient access. Also, supply chain interruptions and economic uncertainties also contributed to market challenges. Thus, owing to aforementioned factors, the market was noted to pose a negative impact on the ovarian cancer treatment market during the pandemic period.
Thus, growing pipeline drugs along with rising government support for R&D funding for cancer studies, favourable reimbursement policies, collaborative research, and strategic approaches further contribute to the market expansion.
Based on cancer type, the global market is segmented into epithelial ovarian cancer, stromal tumors, and germ cell tumors. The epithelial ovarian cancer is expected to lead the market, projecting the highest revenue of USD 5.1 billion by 2032.
Based on treatment type, the global market is classified into targeted therapy drugs, immunotherapy drugs, chemotherapy drugs, hormone therapy drugs, and radiation therapy. The targeted therapy drugs are further categorized as PARP inhibitors, angiogenesis inhibitors, and other targeted therapy drugs. The targeted therapy drugs segment dominated the market accounting for the largest share of 43.7% in 2023.
Based on route of administration, the global market is classified into oral, intravenous, and intraperitoneal. The intravenous route of administration dominated the market and is anticipated to witness a CAGR of over 6.6%.
Based on end-user, the market is classified into hospital pharmacies, retail pharmacies and other end-users. The hospital pharmacies dominated the market accounting for the largest revenue of USD 2 billion in 2023.
The market is characterized by diverse players competing in the industry, leveraging their research capabilities and global presence. Strategic collaborations, extensive R&D investments, and a focus on clinical trials characterize the competitive strategies. The market is dynamic, marked by ongoing advancements, regulatory approvals, and efforts to address unmet medical needs in ovarian cancer treatment.
Prominent players operating in the ovarian cancer treatment drugs industry are as mentioned below:
Market, By Cancer Type
Market, By Treatment Type
Market, By Route of Administration
Market, By End user
The above information is provided for the following regions and countries:
Some of the top ovarian cancer treatment drugs industry players are F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., Astrazeneca, Merck KGaA, Oasmia Pharmaceutical AB, Clovis Oncology, Inc., Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., and Allarity Therapeutics, among others.
Industry size for ovarian cancer treatment drugs reached USD 3.5 billion in 2023 and is projected to be worth USD 6.1 billion by 2032 driven by the high incidence of ovarian cancer globally.
The targeted therapy drugs segment accounted for 43.7% revenue share of the ovarian cancer treatment drugs industry in 2023 and is projected to record substantial growth through 2032 owing to the benefits identifying and combating cancer cells precisely and minimizing harm to healthy cells.
North America industry for ovarian cancer treatment drugs held a sizable revenue share in 2023 and is projected to record robust growth through 2032 attributed to the growing number of patients with ovarian cancer across the region.